Avidity Biosciences, Inc. (RNA)
| Market Cap | 779.88M |
| Revenue (ttm) | 6.79M |
| Net Income (ttm) | -44.36M |
| Shares Out | 37.58M |
| EPS (ttm) | -2.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $20.31 |
| Previous Close | $20.75 |
| Change ($) | -0.44 |
| Change (%) | -2.12% |
| Day's Open | 20.57 |
| Day's Range | 19.85 - 21.50 |
| Day's Volume | 94,439 |
| 52-Week Range | 19.12 - 37.46 |
LA JOLLA, Calif., March 25, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucle...
Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights
LA JOLLA, Calif., March 15, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucle...
LA JOLLA, Calif., Dec. 22, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...
LA JOLLA, Calif., Dec. 21, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...
The unicorn IPO parade is set to begin in the week ahead, with DoorDash and Airbnb leading the way. A total of six IPOs and two SPACs are scheduled to raise $7.2 billion.
LA JOLLA, Calif., Nov. 10, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...
LA JOLLA, Calif., Sept. 28, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucle...
SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Avidity Biosciences, Inc.
SAN DIEGO, Aug. 10, 2020 /PRNewswire/ -- Avidity Biosciences, Inc.
SAN DIEGO, July 27, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Co...
Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.
SAN DIEGO, June 16, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Co...
Shares of Avidity Biosciences Inc. RNA, +55.66% soared 50% in their trading debut on the Nasdaq on Friday after pricing at the top of their initial public offering range, a sign of heightened interest f...
Avidity Biosciences Inc. RNA, , a biotech the specializes in treatments for muscular disorders, priced its initial public offering at $18 a share late Thursday, the high end of its price range.
SAN DIEGO, June 11, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq:RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Con...
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable... [Read more...]
| Industry Biotechnology | IPO Date Jun 12, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol RNA |
Financial Performance
In 2020, RNA's revenue was $6.79 million, an increase of 192.67% compared to the previous year's $2.32 million. Losses were -$44.36 million, 79.3% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for RNA stock is "Strong Buy." The 12-month stock price forecast is 44.33, which is an increase of 118.27% from the latest price.